More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$241186211
EPS
-0.15
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.511343
Previous close
$2.30
Today's open
$2.28
Day's range
$2.15 - $2.35
52 week range
$2.15 - $5.45
show more
CEO
Gaurav D. Shah
Employees
202
Headquarters
Cranbury, NJ
Exchange
NASDAQ Global Market
Shares outstanding
111660283
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2026, and provided recent business updates. “With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027.
Business Wire • Nov 12, 2026

Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that the company will attend Chardan's 10th Annual Healthcare Conference. The company will participate in a panel on Tuesday, October 20, 2026, at 11:30 AM ET and host investor meetings. About Rocket Pharmaceuticals, Inc. Rocket Pha.
Business Wire • Oct 15, 2026

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
Rocket Pharmaceuticals (NASDAQ: RCKT) shares rose 4% on Wednesday after the biotechnology company secured access to up to $150 million under a credit facility with Hercules Capital. The facility strengthens Rocket's financial position and provides additional capital to support its pivotal Phase 2 study of RP-A501 for Danon disease and its broader cardiovascular pipeline.
Proactive Investors • Oct 7, 2026

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
Seeking Alpha • Oct 7, 2026

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported enco.
Business Wire • Oct 7, 2026

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
Rocket Pharmaceuticals NASDAQ: RCKT outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon disease, reporting longer-term Phase I findings, preliminary Phase II observations and an FDA-aligned pivotal study design.
MarketBeat • Oct 7, 2026

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket's financial position and provides access to additional capital to support executi.
Business Wire • Oct 6, 2026

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Zacks Investment Research • Sep 16, 2026

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking Alpha • Sep 15, 2026

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Rocket Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.